Cancer Vaccines - Pipeline Assessment And Market Forecasts To 2017

At present, the global cancer vaccines market is occupied by cervical and prostate cancer vaccines. The vaccines available for cervical cancer are all prophylactic; the brands are Gardasil and Cervarix. The only therapeutic vaccine available in the market is Provenge from Dendreon Corporation.

At present, the global cancer vaccines market is occupied by cervical and prostate cancer vaccines. The vaccines available for cervical cancer are all prophylactic; the brands are Gardasil and Cervarix. The only therapeutic vaccine available in the market is Provenge from Dendreon Corporation.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Cancer-Vaccines-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_HealthcaRe

GlobalData has estimated that the global cervical cancer vaccine market in 2009 was worth $1.41 billion.The global cervical cancer market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5% to reach $2.10 billion in 2017. The cost of three complete dose courses of cervical cancer vaccines ranges from approximately $380 to $390. The global prostate cancer vaccine market is estimated to be $70m in 2010. It is expected reach $2.3 billion in 2017, growing at a CAGR of 66%.

The present pipeline for cancer vaccines seems to be very promising, with numerous molecules present in the Phase II and III stages. From a market perspective, there are going to be multiple launches of vaccines between 2011 and 2013-2015, which is expected to significantly increase the market size and drive growth.

GlobalData, the industry analysis specialist, has released its latest research Cancer Vaccines Pipeline Analysis and Market Forecasts to 2017. It provides key data, information and analysis on the global Cancer vaccines market. The report provides a comprehensive overview of annualized market data from 2001 to 2009, and forecasts for the next eight years to 2017. The report covers the market landscape,market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is
analyzed along with the prevailing unmet need or commercial opportunities of the market. The pipeline analysis covers molecules across all phases of clinical development and gives an overview of the developing trends among pipeline molecules, as well as, an insight into the most promising pipeline drugs, supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for future market competition is also outlined.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Cancer-Vaccines-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_HealthcaRe

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries

GlobalData estimates that the global bone metastases therapeutics market was valued at $1,425m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12% over the next seven years...